These features make lamivudine a more appropriate treatment compared with IFN for patients with decompensated HBV cirrhosis. The recommended dose of lamivudine is 100 mg daily. Because lamivudine ...

Decompensated liver cirrhosis, an advanced stage of cirrhosis often associated with liver failure, currently has no approved therapeutic options other than liver transplantation. At 20 months into ...

For patients with chronic liver disease, statin use is associated with a reduced risk for hepatocellular carcinoma (HCC) and ...

Harvard Medical School researchers have found that statin use significantly reduces the risk of hepatocellular carcinoma (HCC ...

Can-Fite BioPharma (CANF) announced a significant clinical development: the disappearance of episodes of decompensated liver cirrhosis following treatment with Namodenoson under a compassionate ...

Opens in a new tab or window Statin use among patients with chronic liver disease was associated with a reduced risk of liver cancer and hepatic decompensation. Users had a 33% lower risk for ...

Liver cirrhosis is a progressive disease that affects millions worldwide, leading to severe complications such as hepatic decompensation and liver cancer. Despite its significance, early detection ...

A Cleveland Clinic study shows that patients with obesity and fatty liver-related cirrhosis who had bariatric (weight-loss) ...

Primary outcome of interest included the incidence of cirrhosis, with secondary outcomes consisting of associated pathologies (eg, decompensated cirrhosis, hepatocellular carcinoma, liver-related ...